147 related articles for article (PubMed ID: 19446318)
21. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Katsumata N; Yasuda M; Takahashi F; Isonishi S; Jobo T; Aoki D; Tsuda H; Sugiyama T; Kodama S; Kimura E; Ochiai K; Noda K;
Lancet; 2009 Oct; 374(9698):1331-8. PubMed ID: 19767092
[TBL] [Abstract][Full Text] [Related]
22. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
23. Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
Timmermans M; van der Aa MA; Lalisang RI; Witteveen PO; Van de Vijver KK; Kruitwagen RF; Sonke GS
Gynecol Oncol; 2018 Sep; 150(3):446-450. PubMed ID: 30001834
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.
Vergote I; Tropé CG; Amant F; Kristensen GB; Ehlen T; Johnson N; Verheijen RH; van der Burg ME; Lacave AJ; Panici PB; Kenter GG; Casado A; Mendiola C; Coens C; Verleye L; Stuart GC; Pecorelli S; Reed NS; ;
N Engl J Med; 2010 Sep; 363(10):943-53. PubMed ID: 20818904
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival.
Schwartz PE; Rutherford TJ; Chambers JT; Kohorn EI; Thiel RP
Gynecol Oncol; 1999 Jan; 72(1):93-9. PubMed ID: 9889037
[TBL] [Abstract][Full Text] [Related]
26. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Gallardo-Rincon D; Blagden S; Brenton J; Perren TJ; Sundar S; Lord R; Dark G; Hall M; Banerjee S; Glasspool RM; Hanna CL; Williams S; Scatchard KM; Nam H; Essapen S; Parkinson C; McAvan L; Swart AM; Popoola B; Schiavone F; Badrock J; Fananapazir F; Cook AD; Parmar M; Kaplan R; Ledermann JA
Lancet Oncol; 2022 Jul; 23(7):919-930. PubMed ID: 35690073
[TBL] [Abstract][Full Text] [Related]
27. Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin.
Tate S; Nishikimi K; Matsuoka A; Otsuka S; Shozu M
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562736
[TBL] [Abstract][Full Text] [Related]
28. Weekly Carboplatin and Paclitaxel for Ovarian Cancer: The "Finer Points".
Muggia F
Oncologist; 2021 Jan; 26(1):1-3. PubMed ID: 33098242
[TBL] [Abstract][Full Text] [Related]
29. Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer.
Safra T; Waissengrin B; Levy T; Leidner E; Merose R; Matceyevsky D; Grisaru D; Laskov I; Mishaan N; Shayzaf R; Wolf I
Oncologist; 2021 Jan; 26(1):30-39. PubMed ID: 32657524
[TBL] [Abstract][Full Text] [Related]
30. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial.
Clamp AR; James EC; McNeish IA; Dean A; Kim JW; O'Donnell DM; Hook J; Coyle C; Blagden S; Brenton JD; Naik R; Perren T; Sundar S; Cook AD; Gopalakrishnan GS; Gabra H; Lord R; Dark G; Earl HM; Hall M; Banerjee S; Glasspool RM; Jones R; Williams S; Swart AM; Stenning S; Parmar M; Kaplan R; Ledermann JA
Lancet; 2019 Dec; 394(10214):2084-2095. PubMed ID: 31791688
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status.
Takaya H; Nakai H; Murakami K; Tobiume T; Suzuki A; Mandai M; Matsumura N
Int J Clin Oncol; 2018 Aug; 23(4):698-706. PubMed ID: 29572761
[TBL] [Abstract][Full Text] [Related]
32. A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma.
Zhu Y; Zhang W; Li Q; Li Q; Qiu B; Liu H; Liu M; Hu Y
J Cancer; 2017; 8(18):3657-3666. PubMed ID: 29151952
[No Abstract] [Full Text] [Related]
33. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.
Dessai SB; Chakraborty S; Babu TV; Nayanar S; Bhattacharjee A; Jones J; Balasubramanian S; Patil VM
South Asian J Cancer; 2016; 5(2):63-6. PubMed ID: 27275450
[TBL] [Abstract][Full Text] [Related]
34. Concurrent radiotherapy and weekly chemotherapy of 5-fluorouracil and platinum agents for postoperative locoregional recurrence of oesophageal squamous cell carcinoma.
Zhang WW; Zhu YJ; Yang H; Wang QX; Wang XH; Xiao WW; Li QQ; Liu MZ; Hu YH
Sci Rep; 2015 Jan; 5():8071. PubMed ID: 25627119
[TBL] [Abstract][Full Text] [Related]
35. Effect of sun ginseng potentiation on epirubicin and paclitaxel-induced apoptosis in human cervical cancer cells.
Lin Y; Jiang D; Li Y; Han X; Yu D; Park JH; Jin YH
J Ginseng Res; 2015 Jan; 39(1):22-8. PubMed ID: 25535473
[TBL] [Abstract][Full Text] [Related]
36. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013.
Wagner U; Harter P; Hilpert F; Mahner S; Reuß A; du Bois A; Petru E; Meier W; Ortner P; König K; Lindel K; Grab D; Piso P; Ortmann O; Runnebaum I; Pfisterer J; Lüftner D; Frickhofen N; Grünwald F; Maier BO; Diebold J; Hauptmann S; Kommoss F; Emons G; Radeleff B; Gebhardt M; Arnold N; Calaminus G; Weisse I; Weis J; Sehouli J; Fink D; Burges A; Hasenburg A; Eggert C
Geburtshilfe Frauenheilkd; 2013 Sep; 73(9):874-889. PubMed ID: 24771937
[No Abstract] [Full Text] [Related]
37. A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles.
Sorbe B; Graflund M; Nygren L; Horvath G
Oncol Lett; 2013 Apr; 5(4):1140-1148. PubMed ID: 23599753
[TBL] [Abstract][Full Text] [Related]
38. Synergistic effects of apigenin and paclitaxel on apoptosis of cancer cells.
Xu Y; Xin Y; Diao Y; Lu C; Fu J; Luo L; Yin Z
PLoS One; 2011; 6(12):e29169. PubMed ID: 22216199
[TBL] [Abstract][Full Text] [Related]
39. Thinking twice before abandoning first-line chemotherapy in ovarian cancer: report of two cases and literature review. Passing from tri-weekly to weekly regimens.
Marchetti C; Bellati F; Musella A; Napoletano C; Perniola G; Di Donato V; Pignata S; Nuti M; Panici PB
Int J Clin Oncol; 2012 Aug; 17(4):385-9. PubMed ID: 21892670
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
Tiersten AD; Sill MW; Knight D; Muggia F; Garcia AA; Swensen R; Warshal DP; Mannel RS; Fracasso PM
Gynecol Oncol; 2010 Sep; 118(3):303-7. PubMed ID: 20547415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
